All In Biotech

Drug Trial Radar · NCT06400511

A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 477 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

477

Actual

Start

Apr 22, 2024

Primary completion

Sep 9, 2025

Study completion Oct 15, 2025

Sponsor

Sponsor type
Industry
First posted
May 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.

Conditions

  • Blepharitis

Interventions

  • Pimecrolimus 0.3% Ophthalmic OintmentDrug

    Pimecrolimus 0.3% Ophthalmic Ointment will be applied twice a day to both eyelid margins.

  • Placebo Ophthalmic OintmentDrug

    Placebo will be applied twice a day to both eyelid margins.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of Study DrugTime frame: 6 weeks

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Investigative Site

    Pheonix, Arizona

  • Clinical Investigator Site

    Garden Grove, California

  • Clinical Investigator Site

    Glendale, California

  • Clinical Investigator Site

    Inglewood, California

  • Clinical Investigator Site

    Newport Beach, California

  • Clinical Investigator Site

    Petaluma, California

  • Clinical Investigator Site

    Rancho Cordova, California

  • Clinical Investigator Site

    Aurora, Colorado

  • Clinical Investigator Site

    Crystal River, Florida

  • Clinical Investigator Site

    Largo, Florida

  • Clinical Investigator Site

    Tampa, Florida

  • Clinical Investigator Site

    Atlanta, Georgia

  • Clinical Investigator Site

    Morrow, Georgia

  • Clinical Investigator Site

    Pittsburg, Kansas

  • Clinical Investigator Site

    Louisville, Kentucky

  • Clinical Investigator Site

    Havre de Grace, Maryland

  • Clinical Investigator Site

    Medina, Minnesota

  • Clinical Investigator Site

    Kansas City, Missouri

  • Investigative Site

    St Louis, Missouri

  • Clinical Investigator Site

    Washington, Missouri

  • Clinical Investigator Site

    Garner, North Carolina

  • Clinical Investigator Site

    Cincinnati, Ohio

  • Clinical Investigator Site

    Cranberry Township, Pennsylvania

  • Clinical Investigator Site

    Smyrna, Tennessee

  • Clinical Investigator Site

    Austin, Texas

  • Clinical Investigator Site

    Lakeway, Texas

  • Clinical Investigator Site

    San Antonio, Texas

  • Clinical Investigator Site

    Clinton, Utah

  • Clinical Investigator Site

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.